Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Rapid Response Innovation Awards, 2010
    Resting State fMRI as a Biomarker for Parkinson's Disease

    Objective/Rationale
    There is an increasingly interest in finding biomarkers that can objectively evaluate the disease progression and the effects of neuroprotective treatment on the course of...

  • Rapid Response Innovation Awards, 2010
    Identification and Validation of the Modifiers of LRRK2-induced Toxicity

    Objective/Rationale
    Mutations in LRRK2 gene have been identified as an unambiguous cause of rare autosomal dominant forms of PD. A number of useful models have been developed to study the...

  • Rapid Response Innovation Awards, 2010
    CSF Lysosomal Hydrolases' Activity as Possible Marker of Parkinson's Disease

    Objective/Rationale
    Recent studies have linked lysosomal dysfunction to the accumulation of alpha-synuclein oligomers and alpha-synuclein-mediated cell death. Clinical, neuropathological and genetic...

  • Clinical Intervention Awards, 2010
    Gastric-Retentive, Extended-Release Levodopa/Carbidopa Tablets Versus a Reference, Extended-Release Tablet in Parkinson's Disease

    Objective/Rationale
    The objective of this project is to develop a gastric-retentive, extended-release tablet of levodopa/carbidopa (DM-1992) that will result in constant blood levels of levodopa...

  • Clinical Intervention Awards, 2010
    Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease

    Objective/Rationale
    The main objective of this study is to evaluate the effect of ADX48621 (dipraglurant) in reducing levodopa-induced dyskinesia in patients with Parkinson’s disease (PD). ADX48621...

  • Clinical Intervention Awards, 2010
    Acupuncture as a Symptoms & Side Effects Treatment for Fatigue in Parkinson's Disease

    Objective/Rationale:
    Fatigue affects approximately half of all Parkinson’s disease patients and has a major impact on quality of life and disability. Unfortunately, Parkinson’s medications do not...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.